ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more
LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today...
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today...
LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.662251655629 | 3.02 | 3.23 | 2.96 | 213281 | 3.08518011 | CS |
4 | 0.34 | 12.5925925926 | 2.7 | 3.39 | 2.61 | 358726 | 3.0650528 | CS |
12 | -0.15 | -4.70219435737 | 3.19 | 4.13 | 2.53 | 399149 | 3.21638131 | CS |
26 | -1.275 | -29.5480880649 | 4.315 | 5.38 | 2.4505 | 593742 | 3.56001619 | CS |
52 | 2.14 | 237.777777778 | 0.9 | 6.04 | 0.359908 | 633556 | 3.07399032 | CS |
156 | -23.14 | -88.3880825057 | 26.18 | 32 | 0.359908 | 472128 | 4.4342649 | CS |
260 | -26.96 | -89.8666666667 | 30 | 56.5899 | 0.359908 | 406051 | 9.78156825 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.